News | September 07, 2010

Long-Term Data Supports Cypher Over Endeavor in High-Risk Subgroups

September 7, 2010 – New analyses of subgroups from the SORT OUT III study provide detail on longer-term follow-up safety and efficacy outcomes in diabetics and patients with acute coronary syndrome and multiple lesions.Three new analyses of subgroups were presented at the European Society of Cardiology (ESC) meeting last week in Stockholm. These important data add detail to those already published in the March 2010 issue of The Lancet on the clinical outcomes for the primary endpoint in the total population and in multiple subgroups at nine months followup and on clinical outcomes at 18-month followup of the randomized comparison of the Cypher stent and the Endeavor stent.

The initial results of the SORT OUT III study showed significantly reduced adverse events at nine and 18 months for the Cypher sirolimus-eluting coronary stent over Medtronic's Endeavor zotarolimus-eluting stent in an unselected group of 2,332 patients undergoing coronary intervention in real-world clinical practice. The authors reported that subgroup analysis of the primary endpoint of nine-month major adverse cardiac events (MACE, defined as a composite of cardiac death, myocardial infarction [MI] or target vessel revascularization [TVR]) were also consistent across all subgroups.

The new data from ESC provide important additional information on longer-term outcomes at 18 months in three key groups of patients that are at higher risk of adverse events when undergoing coronary intervention, namely patients with diabetes, acute coronary syndromes and treatment of multiple lesions. These data confirm that the significant reductions in major adverse events in these subgroups seen at nine months with the Cypher compared to the Endeavor were sustained through 18 months of followup and provide important details of how the components of MACE contribute to the reduction in major adverse events.

Diabetics
Among the high-risk diabetic patient population in SORT OUT III, the incidence of MACE at 18 months was significantly reduced by 74 percent with Cypher vs. Endeavor (4.8 percent in the Cypher group vs. 18.3 percent in the Endeavor group; hazard ratio 4.05; 95 percent confidence intervals: 1.86-8.82). This difference was driven by statistically significant reductions in death, MI, TVR and TLR favoring the Cypher stent. In the Cypher group, the incidence of MACE was also significantly reduced by 46 percent compared to the Endeavor in patients without diabetes (4.5 percent in the Cypher group vs. 8.3 percent in the Endeavor group; hazard ratio 1.87, 95 percent confidence intervals: 1.30-2.69).

Coronary Syndromes
Among patients with acute coronary syndrome in SORT OUT III (defined as patients with unstable angina or myocardial infarction), the incidence of MACE at 18 months was reduced by 43 percent with Cypher vs. Endeavor (5 percent in the Cypher group vs. 8.7 percent in the Endeavor group; hazard ratio 1.78; 95 percent confidence intervals: 1.10-2.88). This difference was driven by a statistically significant reduction in TLR and TVR favoring the Cypher. In the Cypher group the incidence of MACE also was reduced by 60 percent compared to the Endeavor stent in patients with stable angina (4.2 percent in the Cypher group vs. 10.4 percent in the Endeavor group; hazard ratio 2.53, 95 percent confidence intervals: 1.60-4.02).

Multiple Lesions
Among the high-risk group treated for disease in multiple lesions in SORT OUT III, the incidence of MACE at 18 months was reduced by 80 percent with Cypher vs. Endeavor (2.6 percent in the Cypher group vs. 13.2 percent in the Endeavor group; hazard ratio 5.29; 95 percent confidence intervals: 2.59-10.8). This difference was driven by statistically significant reductions in death, MI and TVR favoring Cypher. In the Cypher group the incidence of MACE was also significantly reduced by 35 percent compared to the Endeavor in patients treated for disease in one lesion (5.4 percent in the Cypher group vs. 8.3 percent in the Endeavor group).

Related Content

New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
Overlay Init